Elizabeth H Eustis1, Matthew W Gallagher2, Julianne W Tirpak3, Maya Nauphal3, Todd J Farchione3, David H Barlow3. 1. Center for Anxiety and Related Disorders, Department of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave. 2(nd) Floor, Boston, MA 02215, United States of America. Electronic address: eeustis@bu.edu. 2. Department of Psychology, The University of Houston, Health and Biomedical Sciences Building, 4849 Calhoun Rd - Room 373, Houston, TX 77204, United States of America. 3. Center for Anxiety and Related Disorders, Department of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave. 2(nd) Floor, Boston, MA 02215, United States of America.
Abstract
OBJECTIVE: To examine whether the Unified Protocol (UP) remains equivalent to single-disorder protocols (SDPs) in the treatment of anxiety disorders at 12-month follow-up. METHOD: We report results from the 12-month follow-up of a recent randomized equivalence trial [1]. Data are from 179 participants (55.31% female sex, 83.24% White, average age 30.66) who met criteria for a principal anxiety disorder and were randomized to either the UP or SDP conditions. Consistent with the parent trial, the primary outcome was principal diagnosis clinician severity rating (CSR) from the Anxiety Disorder Interview Schedule (ADIS). Secondary outcomes included anxiety, depression, and impairment. Missing data were accommodated using multiple imputation (10,000 imputed data sets) under a missing at random assumption. Equivalence between the UP and SDPs was tested using slope difference scores from latent growth models and 95% confidence interval of between-condition effect sizes. RESULTS: The results indicated that the UP and SDP conditions remained equivalent with regard to principal diagnosis clinician severity rating at 12-month follow-up. In addition, there were no significant differences between conditions on secondary outcomes at 12-month follow-up. CONCLUSIONS: The UP continues to yield outcomes comparable to SDPs at 12-month follow-up, and therefore provides a single intervention that can be used to treat the most commonly occurring psychiatric disorders with durable effects.
OBJECTIVE: To examine whether the Unified Protocol (UP) remains equivalent to single-disorder protocols (SDPs) in the treatment of anxiety disorders at 12-month follow-up. METHOD: We report results from the 12-month follow-up of a recent randomized equivalence trial [1]. Data are from 179 participants (55.31% female sex, 83.24% White, average age 30.66) who met criteria for a principal anxiety disorder and were randomized to either the UP or SDP conditions. Consistent with the parent trial, the primary outcome was principal diagnosis clinician severity rating (CSR) from the Anxiety Disorder Interview Schedule (ADIS). Secondary outcomes included anxiety, depression, and impairment. Missing data were accommodated using multiple imputation (10,000 imputed data sets) under a missing at random assumption. Equivalence between the UP and SDPs was tested using slope difference scores from latent growth models and 95% confidence interval of between-condition effect sizes. RESULTS: The results indicated that the UP and SDP conditions remained equivalent with regard to principal diagnosis clinician severity rating at 12-month follow-up. In addition, there were no significant differences between conditions on secondary outcomes at 12-month follow-up. CONCLUSIONS: The UP continues to yield outcomes comparable to SDPs at 12-month follow-up, and therefore provides a single intervention that can be used to treat the most commonly occurring psychiatric disorders with durable effects.
Authors: Todd J Farchione; Christopher P Fairholme; Kristen K Ellard; Christina L Boisseau; Johanna Thompson-Hollands; Jenna R Carl; Matthew W Gallagher; David H Barlow Journal: Behav Ther Date: 2012-01-18
Authors: David H Barlow; Todd J Farchione; Jacqueline R Bullis; Matthew W Gallagher; Heather Murray-Latin; Shannon Sauer-Zavala; Kate H Bentley; Johanna Thompson-Hollands; Laren R Conklin; James F Boswell; Amantia Ametaj; Jenna R Carl; Hannah T Boettcher; Clair Cassiello-Robbins Journal: JAMA Psychiatry Date: 2017-09-01 Impact factor: 21.596
Authors: Ladislav Timulak; Derek Richards; Louise Bhandal-Griffin; Patrick Healy; Juliana Azevedo; Graham Connon; Elaine Martin; Aoife Kearney; Conor O'Kelly; Angel Enrique; Nora Eilert; Sorcha O'Brien; Siobhan Harty; Alberto González-Robles; Elizabeth H Eustis; David H Barlow; Todd J Farchione Journal: Trials Date: 2022-08-31 Impact factor: 2.728